Global

The EU’s proposed new on off-label prescribing is just another way of kicking the issue into the long grass, writes Reflector.

Rohit Sood outlines five critical factors for companies entering this blossoming market.

March 11, 2015.

March 6, 2015.

Just as the medicine adaptive pathways to patients (MAPPs) gains currency in the world of medicine, the EU has come up with STAMP, a new expert group intended to assist the process, but which might well suffocate it. Reflector reports.

President Obama's January announcement of an initiative in precision medicine has set Europe a-flutter over the term 'personalized medicine', writes Peter O'Donnell.

The debate around NICE's threshold for cost effectiveness has always been heated; recent theories add more fuel to the fire, writes Leela Barham.

New EU group could ultimately end up handcuffing much-needed efforts to modernize drug authorization.

South Africa may have the most developed market for biopharmaceuticals on the African continent, but there are a few critical shortcomings, writes William Looney.

"Global free-riding" is the perception that the U.S. is subsidizing drugs for the rest of the world due to its high drug prices compared to other countries in the world.

February 17, 2015.

The European Commission’s (EC) decision to withdraw its investigation into the UK Government's Patent Box scheme is positive news for British innovators, writes Michael Jaeger.

Josh Baxt casts his eye over what to look out for in the diabetes and obesity treatment markets.

A new analysis shows South Korea to be the most attractive early phase destination based on the availability of global and regional suppliers, patient pool and the current regulatory scenario of the country.

The French pharmaceutical market is forecast to grow at a "tepid" CAGR of 0.7% from $46.2 billion in 2014 to $48.2 billion by 2020, according to GlobalData.

Pharma and healthcare are among the many areas being viewed with increasing attention inside and outside Greece, following the victory in the country’s elections of the radical left-wing, anti-austerity Syriza party.

New competition commissioner steps into the unenviable role of trying to solve two particularly contentious pharma firestorms.

With a track record of surviving successive economic crises, the battle-tested Argentinian pharma industry has developed into a powerful leader in markets across the Latin America region.

Findings from the joint report on the occurrence of antimicrobial resistance in bacteria from humans and food-producing animals.

Franz Humer, former CEO and chairman of Roche, has joined BIAL, Portugal's largest pharma company, as a non-executive board member.

Several vaccine candidates are moving into larger clinical trials, supported by government and industry efforts to address manufacturing and research challenges. Jill Wechsler reports.

2014 was a banner year for investment in biotech, and there is little sign of decline. With an unprecedented $100m Series C round of financing, Innovent has demonstrated this optimism extends as far as China.

Brussels correspondent Reflector asks, what attitude will the new EC for competition, Margrethe Vestager, adopt to the pharmaceutical industry?

Brand success can hinge on discovering the deeper motivations of customers and addressing the cognitive biases that result.

Leela Barham looks at some of the questions that still need to be asked of England's controversial Cancer Drug Fund.

Pharm Exec’s annual report highlights the key scientific, commercial, and reputational trends shaping the industry in the year ahead.

The Canadian R&D industry, which boasts a rich history of drug innovation, celebrates a series of anniversaries.

The European Union's extensive links with the US FDA and Health Canada have reached a further level of maturity, writes Peter O' Donnell.

The entry into force of the new EU clinical trials regulation last June is really little more than a virtual event. The new rules will apply only once the EU Clinical Trials Portal and Database now under development are fully operational.

Jill E. Sackman and Michael Kuchenreuther look at some of the pricing and reimbursement challenges in the UK and offer strategies manufacturers should consider for sustainable success.